Idiopathic pulmonary fibrosis (IPF) is a progressive and life-limiting lung disease characterised by scarring (fibrosis) of the lung tissue which primarily affects older adults. The exact cause of the disease is unknown, however, certain risk factors, such as a history of smoking, and genetic predisposition, may increase the likelihood of developing the disease.

While there is no cure for IPF, two antifibrotic medications, have been approved for use in some regions and have shown efficacy in slowing the decline in lung function. However, patients and clinicians are seeking new treatments that offer improved tolerability, efficacy, and symptom management.

While the opportunity is vast, changes in the IPF landscape present new and significant challenges that companies will need to navigate with different strategies and approaches to ‘what has been done before’. These include expanding treatment options, shift towards combination and personalised treatment paradigm, pressure to expedite early-stage development, opposition to placebo-control designs and intensifying competition for trial participants and investigators.

This whitepaper explores the evolving landscape of IPF and aims to empower early-stage biopharmaceutical teams with actionable expert insights into how they may meet emerging challenges and chart a new roadmap to success in IPF. Read the whitepaper to explore:

• Optimised preclinical phases for IPF trials
• Proactive and agile regulatory strategies
• Successfully collaborating with patient advocacy groups
• Leveraging novel protocol designs
• Improved trial and clinical development planning